Singapore-Stanford Biodesign announces appointment of new Directors
PUBLISHED: 09 Feb 2018
Singapore-Stanford Biodesign (SSB) is glad to announce the appointment of new directors that will lead SSB to evolve and meet the needs of the medtech ecosystem in Singapore and Asia.
Mr. Justin Phoon is appointed full Program Director position with effect from 1st January 2018, following Mr. Phoon's appointment as Co-Programme Director alongside Co-Programme Director Mr. Peh Ruey Feng in 2017. Joining Mr. Justin Phoon is Dr. Mary Kan who is appointed Deputy Director position with effect from 6th February 2018. Mr. Peh Ruey Feng will retain his position as the SSB Co-Programme Director.
Justin started his career in Zimmer before taking up a sales role in Medtronic. He was holding the role of Sales and Market Development Manager for their neuromodulation business across ASEAN just prior to his SSB Fellowship in 2012.
Mary was previously with ST Engineering working on formulation of new business entry strategy and facilitating cross-institutional partnerships with local agencies, health services and industry. Prior to joining SSB as a Fellow in 2015, Mary was with DSO National Laboratories focusing on preclinical and clinical research.
Welcome on board Justin and Mary!
2) Dr. Mary Kan